ANAB
Anaptysbio Inc
NASDAQ · Biotechnology
$49.73
+1.83 (+3.82%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 89.05M | 78.77M | 175.23M | 183.45M | 146.61M |
| Net Income | -141,681,920 | -112,794,098 | 2.08M | 2.09M | 1.41M |
| EPS | — | — | — | — | — |
| Profit Margin | -159.1% | -151.2% | 1.2% | 1.1% | 1.0% |
| Rev Growth | +13.1% | +13.1% | -0.6% | +5.3% | +16.8% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 573.48M | 573.48M | 265.61M | 219.73M | 209.35M |
| Total Equity | 114.99M | 114.99M | 847.24M | 894.48M | 927.05M |
| D/E Ratio | 4.99 | 4.99 | 0.31 | 0.25 | 0.23 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | -160,399,328 | -134,789,351 | 3.17M | 3.06M | 2.67M |
| Free Cash Flow | — | — | 1.41M | 1.04M | 763.9K |